Loading
A phase 3 trial of Doxorubicin, Pegylated liposomal doxorubicin, Topotecan, Gemcitabine, Pembrolizumab and Bevacizumab in ovarian cancer, run by GlaxoSmithKline, now recruiting.
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) is a phase 3 interventional study registered as NCT07286266 by GlaxoSmithKline, with 450 participants planned, started 2026-06-18 and due to reach its primary completion in 2029-12-17. Interventions recorded: Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD), Topotecan, Gemcitabine and Pembrolizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pegylated liposomal doxorubicin, Topotecan, Platinum-resistant ovarian cancer, Gemcitabine and the tag pipeline.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Pegylated liposomal doxorubicin, Doxorubicin, Gemcitabine, Ovarian cancer and the tag pipeline.
Shares Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Ovarian cancer and the tag pipeline.
Shares GSK, Doxorubicin and the tag pipeline.
Shares GSK, Bevacizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/